Investment to Accelerate AI Innovation in Oncology, Personalized Medicine, and Drug Development
May 21, 2025
Establishing an AI-Centric R&D Ecosystem in Cambridge and London
BioNTech will open two new UK-based research centres: a Cambridge site focused on AI-integrated genomics, oncology, and regenerative medicine, and a London headquarters housing an AI hub operated by InstaDeep, BioNTech’s AI subsidiary, specializing in computational biology and drug discovery. These centres will drive forward AI-first approaches in R&D and enhance UK innovation leadership.
Accelerating AI for Personalized Cancer Therapies
As part of this initiative, BioNTech aims to deliver AI-enabled personalized cancer treatments to up to 10,000 UK patients by 2030 via early-stage clinical trials.
“This investment strengthens our AI research capabilities and supports our mission to transform cutting-edge science into effective therapies,” — Prof. Uğur Şahin, CEO, BioNTech
Driving Job Creation and AI Talent Development
The expansion will generate over 400 new jobs across AI engineering, clinical operations, and biomedical research—boosting the UK’s high-skill talent base and future workforce in AI and biotech.
UK Government: AI Investment Is a Cornerstone of Life Sciences Growth
The UK government hailed the deal as one of the largest life sciences investments in its history, marking a pivotal move toward establishing the country as a global hub for AI-driven biopharma innovation.
BioNTech’s Vision: AI as the Future of Biopharmaceutical R&D
BioNTech aims to integrate AI and machine learning into every phase of drug development—from discovery to clinical trial optimization—pioneering a data-first R&D model to accelerate breakthrough therapies.
For more information, visit: www.biontech.com
By
